Eyal Gottlieb, MBA, PhD
Department of Cancer Biology, Division of Discovery Science
About Dr. Eyal Gottlieb
My research focuses on unraveling the metabolic control of cancer, aiming to elucidate physiological and pathological metabolic changes that regulate cell fate and inform new therapeutic strategies. Employing interdisciplinary methods—including metabolomics, clinical, and pre-clinical models—I investigate molecular mechanisms, biomarkers, and therapeutic opportunities in cancer and other metabolic disorders.
I earned my PhD in Cancer Biology at the Weizmann Institute, where I uncovered the pathophysiological role of p53 in cell death. My postdoctoral training included an EMBO fellowship at the University of Chicago and a Leukemia and Lymphoma Society Special Fellowship at the University of Pennsylvania, where I developed a deep interest in cancer metabolism. I launched my independent research career in 2003 at the Cancer Research UK Beatson Institute and later transitioned to the Technion–Israel Institute of Technology, where I led the Rappaport Institute for Research in the Medical Sciences. In January 2023, I joined the University of Texas MD Anderson Cancer Center as Vice President for Research and Professor in the Department of Cancer Biology.
Throughout my career, I have made significant contributions to cancer metabolism research. Key discoveries include the identification of onco-metabolic signaling cascades linked to the inactivation of tumor suppressors and TCA cycle enzymes, such as succinate dehydrogenase (SDH) and fumarate hydratase (FH). These findings revealed that TCA cycle metabolites signal from mitochondria to the cytosol and nucleus, inhibiting α-ketoglutarate-dependent dioxygenases and hence perturbing HIF degradation, and histone/DNA demethylation. Additionally, my research has defined metabolic vulnerabilities in FH- and SDH-deficient cells, uncovering novel therapeutic opportunities.
My work has also explored metabolic stress adaptations in cancer, demonstrating the essential role of acetate as a carbon source under stress conditions and validating ACSS2 as a therapeutic target. Leveraging metabolomics, I identified plasma biomarkers that reliably diagnose FH-deficient renal cell carcinoma. In metabolic dysfunction-associated steatotic liver disease (MASLD), I discovered that accelerated serine synthesis via reversed SHMT2 activity leads to glycine depletion, glutathione deficiency, and heightened xenobiotic sensitivity in hepatic steatosis.
These discoveries collectively advance our understanding of cancer metabolism and offer promising avenues for clinical translation.
Present Title & Affiliation
Primary Appointment
Vice President, Research, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor and R.E. Bob Smith Distinguished Chair in Cancer Biology, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2020 | Technion – Israel Institute of Technology, IL, MBA, Faculty of Industrial Engineering and Management |
| 1998 | Weizmann Institute of Science, IL, PhD, Molecular Cell Biology |
| 1993 | Weizmann Institute of Science, IL, MSc, Molecular Cell Biology |
| 1990 | The Hebrew University of Jerusalem, IL, BSc, Agriculture (Animal Sciences) |
Postgraduate Training
| 1999-2003 | Postgraduate Fellow, University of Pennsylvania, Pennsylvania, PA |
| 1998-1999 | Postgraduate Fellow, University of Chicago, Chicago, IL |
Experience & Service
Academic Appointments
Professor, Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, 2016 - 2022
Professor of Molecular Cell Biology, University of Glasgow, Glasgow, 2009 - 2018
Senior Research Group leader, Cancer Research UK, Beatson Institute, Glasgow, 2009 - 2018
Research Group Leader, Cancer Research UK, Beatson Institute, Glasgow, 2003 - 2009
Administrative Appointments/Responsibilities
VP, Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Division Head, Department of Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Vice Dean for Research, Department of Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, 2020 - 2022
Director, Department of Rappaport Family Institute for Research in the Medical Sciences, Technion – Israel Institute of Technology, Haifa, 2020 - 2022
Director, Department of Cancer Metabolism Research Unit, Cancer Research UK, Beatson Institute, Glasgow, 2013 - 2018
Selected Publications
Peer-Reviewed Articles
- Ghrayeb A, Finney AC, Agranovich B, Peled D, Anand SK, McKinney MP, Sarji M, Yang D, Weissman N, Drucker S, Fernandes SI, Fernandez-Garcia J, Mahan K, Abassi Z, Tan L, Lorenzi PL, Traylor J, Zhang J, Abramovich I, Chen YE, Rom O, Mor I, Gottlieb E. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab 36(1):116-129.e7, 2024. PMID: 38171331.
- Zheng L, Zhu ZR, Sneh T, Zhang WT, Wang ZY, Wu GY, He W, Qi HG, Wang H, Wu XY, Fernandez-Garcia J, Abramovich I, Xu YZ, Zhang J, Gottlieb E. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma. J Clin Invest 133(11), 2023. PMID: 37053010.
- Willi L, Abramovich I, Fernandez-Garcia J, Agranovich B, Shulman M, Milman H, Baskin P, Eisen B, Michele DE, Arad M, Binah O, Gottlieb E. Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients. Int J Mol Sci 23(17), 2022. PMID: 36077200.
- Savino AM, Fernandes SI, Olivares O, Zemlyansky A, Cousins A, Markert EK, Barel S, Geron I, Frishman L, Birger Y, Eckert C, Tumanov S, MacKay G, Kamphorst JJ, Herzyk P, Fernandez-Garcia J, Abramovich I, Mor I, Bardini M, Barin E, Janaki-Raman S, Cross JR, Kharas MG, Gottlieb E, Izraeli S, Halsey C. Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment is dependent on Stearoyl CoA desaturase. Nat Cancer 1(10):998-1009, 2020. PMID: 33479702.
- van der Reest J, Lilla S, Zheng L, Zanivan S, Gottlieb E. Proteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress. Nat Commun 9(1):1581, 2018. PMID: 29679077.
- Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, Helgason GV, Gottlieb E. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med 23(10):1234-1240, 2017. PMID: 28920959.
- Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen PO, Weinstock A, Wagner A, Lindsay SL, Hock AK, Barnett SC, Ruppin E, Morkve SH, Lund-Johansen M, Chalmers AJ, Bjerkvig R, Niclou SP, Gottlieb E. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 17(12):1556-68, 2015. PMID: 26595383.
- Cardaci S, Zheng L, MacKay G, van den Broek NJ, MacKenzie ED, Nixon C, Stevenson D, Tumanov S, Bulusu V, Kamphorst JJ, Vazquez A, Fleming S, Schiavi F, Kalna G, Blyth K, Strathdee D, Gottlieb E. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol 17(10):1317-26, 2015. PMID: 26302408.
- Zheng L, Cardaci S, Jerby L, MacKenzie ED, Sciacovelli M, Johnson TI, Gaude E, King A, Leach JD, Edrada-Ebel R, Hedley A, Morrice NA, Kalna G, Blyth K, Ruppin E, Frezza C, Gottlieb E. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat Commun 6(None):6001, 2015. PMID: 25613188.
- Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27(1):57-71, 2015. PMID: 25584894.
- Duran RV, MacKenzie ED, Boulahbel H, Frezza C, Heiserich L, Tardito S, Bussolati O, Rocha S, Hall MN, Gottlieb E. HIF-independent role of prolyl hydroxylases in the cellular response to amino acids. Oncogene 32(38):4549-56, 2013. PMID: 23085753.
- Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, Watson DG, Szlosarek P, Frezza C, Gottlieb E. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab 1(1):12, 2013. PMID: 24280230.
- Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424):458-462, 2012. PMID: 23064226.
- Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G, Watson DG, Gottlieb E. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 6(9):e24411, 2011. PMID: 21912692.
- Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477(7363):225-8, 2011. PMID: 21849978.
- Schug ZT, Gonzalvez F, Houtkooper RH, Vaz FM, Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ 18(3):538-48, 2011. e-Pub 2011. PMID: 21072056.
- Tennant DA, Gottlieb E. HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. J Mol Med (Berl) 88(8):839-49, 2010. PMID: 20383689.
- Tennant DA, Frezza C, MacKenzie ED, Nguyen QD, Zheng L, Selak MA, Roberts DL, Dive C, Watson DG, Aboagye EO, Gottlieb E. Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene 28(45):4009-21, 2009. PMID: 19718054.
- Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ, Petit PX, Vaz FM, Gottlieb E. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol 183(4):681-96, 2008. PMID: 19001123.
- MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 27(9):3282-9, 2007. PMID: 17325041.
- Selak MA, Duran RV, Gottlieb E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Acta 1757(5-6):567-72, 2006. PMID: 16797480.
- Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77-85, 2005. PMID: 15652751.
Invited Articles
- Boulahbel H, Duran RV, Gottlieb E. Prolyl hydroxylases as regulators of cell metabolism. Biochem Soc Trans 37(Pt 1):291-4, 2009. PMID: 19143649.
Other Articles
- Peled D, Casey R, Gottlieb E Knowledge-Based Therapeutics for Tricarboxylic Acid (TCA) Cycle-Deficient Cancers. Cold Spring Harb Perspect Med 14(9):None, 2024. PMID: 38503501.
- Schug ZT, Vande Voorde J, Gottlieb E The metabolic fate of acetate in cancer. Nat Rev Cancer 16(11):708-717, 2016. PMID: 27562461.
- Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S, Gottlieb E Cancer metabolism at a glance. J Cell Sci 129(18):3367-73, 2016. PMID: 27635066.
- Mackay GM, Zheng L, van den Broek NJ, Gottlieb E Analysis of Cell Metabolism Using LC-MS and Isotope Tracers. Methods Enzymol 561(None):171-96, 2015. PMID: 26358905.
- Nowicki S, Gottlieb E Oncometabolites: tailoring our genes. FEBS J 282(15):2796-805, 2015. PMID: 25864878.
- Chaneton B, Gottlieb E Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37(8):309-16, 2012. PMID: 22626471.
- Schug ZT, Frezza C, Galbraith LC, Gottlieb E The music of lipids: how lipid composition orchestrates cellular behaviour. Acta Oncol 51(3):301-10, 2012. PMID: 22283492.
- Frezza C, Pollard PJ, Gottlieb E Inborn and acquired metabolic defects in cancer. J Mol Med (Berl) 89(3):213-20, 2011. PMID: 21301796.
- Tennant DA, Duran RV, Gottlieb E Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4):267-77, 2010. PMID: 20300106.
- King A, Gottlieb E Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr Opin Cell Biol 21(6):885-93, 2009. PMID: 19850457.
- Schug ZT, Gottlieb E Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim Biophys Acta 1788(10):2022-31, 2009. PMID: 19450542.
- Tennant DA, Duran RV, Boulahbel H, Gottlieb E Metabolic transformation in cancer. Carcinogenesis 30(8):1269-80, 2009. PMID: 19321800.
- Frezza C, Gottlieb E Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 19(1):4-11, 2009. PMID: 19101633.
- Gonzalvez F, Gottlieb E Cardiolipin: setting the beat of apoptosis. Apoptosis 12(5):877-85, 2007. PMID: 17294083.
- King A, Selak MA, Gottlieb E Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25(34):4675-82, 2006. PMID: 16892081.
Editorials
- Krauss D, Gottlieb E. Restraining colorectal cancer with alphaKG. Nat Cancer 1(3):267-269, 2020. PMID: 35122033.
- Kamphorst JJ, Gottlieb E. Commentary: Friendly neighbours feed tumour cells. Nature 536(None):401-402, 2016. PMID: 27509862.
- van der Reest J, Gottlieb E. Commentary: Anti-cancer effects of vitamin C revisited. Cell Res 26(None):269-270, 2016. PMID: 26768769.
- Schug ZT, Vande Voorde J, Gottlieb E. Commentary: The Nurture of tumors can drive their metabolic phenotype. Cell Metab 23(None):391-392, 2016. PMID: 26959177.
- Chaneton B, Gottlieb E. PGAMgnam style: a glycolytic switch controls biosynthesis. Cancer Cell 22(5):565-6, 2012. PMID: 23153529.
- Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 17(1):7-9, 2010. PMID: 20129244.
Selected Presentations & Talks
Local Presentations
- 2024. Glutathione metabolism in health and disease: from diagnostic tools to therapeutic opportunities. Invited. Department Seminar Series. Houston, TX, US.
- 2024. Environmental metabolic vulnerabilities in hematologic malignancies. Invited. Enjoy Science. Houston, TX, US.
- 2024. Environmental and genetic metabolic vulnerabilities of cancer. Invited. Metabolic Hallmarks. Houston, TX, US.
- 2023. Direct biochemical link between proline biosynthesis and redox stress control. Invited. Joint meeting: MD Anderson - Princess Margaret Cancer Centers. Houston, TX, US.
- 2023. Metabolic Hallmark of Cancer. Invited. GSBS Cancer Biology Retreat. Houston, TX, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Inaugural MIMIG symposium. Houston, TX, US.
- 2023. When Metabolism Meets Cancer. Invited. Understanding our Breakthroughs. Houston, TX, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Cancer and Metabolism. Houston, TX, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Department Seminar Series. Houston, TX, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Center for Cancer Epigenetics Retreat. Round Top, TX, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Department Seminar Series. Houston, TX, US.
National Presentations
- 2025. Metabolic Pathways in Cancer. Invited. The Wistar Institute Trainee Symposium. Philadelphia, PA, US.
- 2024. Glutathione metabolism in health and disease. Conference. Diabetes and Cancer Interface Symposium: Connecting the Dots, US.
- 2024. Glutathione metabolism in health and disease: from diagnostic tools to therapeutic opportunities. Invited. Lexington, KY, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Stanford, CA, US.
- 2023. Targeting genetic and environmental metabolic vulnerabilities in cancer. Invited. Virtual, US.
- 2022. Metabolic synthetic lethality is an effective strategy to target hereditary cancer syndromes with TCA cycle deficiency. Conference. Human Genome Meeting. Tel Aviv, IL.
- 2022. Translating current metabolic knowledge into future cancer clinical management. Conference. Cancer Meeting. Rehovot, IL.
- 2021. The druggable metabolic landscape of cancer. Invited. Virtual, IL.
- 2019. Metabolic adaptation to prolonged resource exhaustion. Conference. Stress, Inflammation & Cancer. Rehovot, IL.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. Edinburgh, GB.
- 2017. How metabolism affects cell growth in cancer. Conference. Oncology at the Limits Conference. London, GB.
International Presentations
- 2025. New Therapeutic Opportunities in Glutathione Metabolism. Conference. Redox Biology in Health and Disease. Riviera Maya, MX.
- 2025. Redox metabolism in health and disease. Invited. Distinguished Professor Lectures Series. Montreal, CA.
- 2025. Liver Metabolism and Disease Progression. Conference. Experimental Hepatology. Lyon, FR.
- 2025. Metabolic Pathways in Cancer: Insights and Innovations. Conference. From tumor biology to future clinical solutions. Athens, GR.
- 2025. The crosstalk between metabolism, epigenetics and genomic integrity. Invited. Frankfurt, DE.
- 2024. Glutathione metabolism in health and disease. Conference. Symposium on Hormones and Cell Regulation: Cancer Signalling and Metabolism. Mont Sainte-Odile Abbey, FR.
- 2024. Metabolic liabilities of fatty liver disease. Invited. Berlin, DE.
- 2024. The Opportunities and Challenges of Targeting Essential Metabolic Traits of Leukemic Stem Cells. Conference. EHA Research Conference. Borovets, BG.
- 2023. The multiple faces of two-carbon metabolism in cancer progression and therapeutics. Conference. Metabolism and Cancer Conference. Nice, FR.
- 2022. Fumarate-induced redox state creates valuable diagnostic circulating biomarkers and exploitable metabolic vulnerabilities. Conference. Mitochondria: Past and Present. Ein Gedi, IL.
- 2022. Fumarate-induced redox state creates valuable diagnostic circulating biomarkers and exploitable metabolic vulnerabilities. Conference. Workshop on Mitochondria and Cancer. Glasgow, GB.
- 2022. Exploiting tumors’ redox state for effective diagnosis and treatment. Conference. Abcam Conference: Cancer Metabolism. London, GB.
- 2022. Revealing and exploiting cancer’s metabolic vulnerabilities. Conference. International Society of Cancer Metabolism Meeting. Torino, IT.
- 2022. Chemoresistance can be modulated by a metabolic crosstalk between proline and glutathione biosynthesis. Conference. EACR Annual Meeting. Seville, ES.
- 2022. Targeting Metabolic Vulnerabilities of Cancer. Invited. Boston, US.
- 2022. Translating current metabolic knowledge into future cancer clinical management. Conference. CABIMER meeting on Cancer and Metabolism. Siville, ES.
- 2021. Sensitizing cells to chemotherapy by targeting metabolic adaptation to redox stress. Invited. EMBO Workshop on Immunometabolism. Sitges, ES.
- 2021. Acetate joins the druggable metabolic landscape of cancer. Conference. AICC Annual Meeting. Torino, IT.
- 2021. Sensitizing cells to chemotherapy by targeting metabolic adaptation to redox stress. Invited. Student's Meeting. Virtual, AT.
- 2021. Acetate joins the druggable metabolic landscape of cancer. Conference. The 4th International ADELIS Congress. Virtual, FR.
- 2021. Acetate joins the druggable metabolic landscape of cancer. Conference. CRCT Conference. Toulouse, FR.
- 2021. Acetate joins the druggable metabolic landscape of cancer. Conference. Nature Conference on Metabolism. Virtual, CN.
- 2021. The druggable metabolic landscape of cancer. Invited. SIBBM Annual Meeting. Virtual, IT.
- 2020. The druggable metabolic landscape of cancer. Invited. Virtual, NO.
- 2020. Metabolic vulnerabilities of leukemic cells. Invited. Shanghai, CN.
- 2020. Stable isotope tracing for studying cancer vulnerabilities and biomarkers. Conference. Chinese Science Foundation Meeting. Shanghai, CN.
- 2019. Stable isotope tracing in metabolomics and proteomics for studying redox stress. Conference. Advances in Biomedical Mass Spectrometry. Kolkata, IN.
- 2019. Targeting metabolic vulnerabilities of cancer. Invited. Paris, FR.
- 2019. Cancer Metabolism. Conference. CRUK Marshall Symposia. Littlehampton, GB.
- 2019. Targeting metabolic vulnerabilities of cancer. Conference. The 3rd Australian Cancer and Metabolism Meeting. Sydney, AU.
- 2019. Metabolic adaptation to prolonged resource exhaustion. Conference. Nature Conference on Cellular Metabolism. Xiamen, CN.
- 2019. Metabolic consequences and liabilities of TCA cycle truncation in cancer. Conference. AACR Annual Meeting. Atlanta, US.
- 2019. Targeting Metabolic Vulnerabilities of Cancer. Conference. Metabolism Cancer & Beyond. Toulouse, FR.
- 2018. Metabolic Vulnerabilities of Cancer. Conference. Metabolites as Signaling Molecules. Seattle, US.
- 2018. Oncometabolism and metabolic vulnerabilities of TCA-truncated cancers. Conference. 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Dublin, IE.
- 2018. Metabolic Targets in Cancer. Panelist. ESMO Annual Meeting. Munich, DE.
- 2018. Metabolic regulation of cells' fate. Conference. ECDO Annual Meeting. St. Petersburg, RU.
- 2018. Targeting metabolic vulnerabilities of cancer. Conference. Europe-Korea Conference on Science and Technology. Glasgow, GB.
- 2018. Identifying and exploiting cancer's metabolic liabilities. Invited. Erlangen, DE.
- 2018. Targeting Metabolic Vulnerabilities of TCA-Deficient Tumors. Conference. EACR 25th Biennial Congress. Amsterdam, NL.
- 2018. Metabolic adaptations of TCA cycle-truncated tumors. Conference. Abcam Conference: Cancer and Metabolism. Cambridge, GB.
- 2018. Metabolic Vulnerabilities of Cancer. Conference. Norwegian Cancer Symposium. Oslo, NO.
- 2018. Oncometabolism: from new modules to therapeutic opportunities. Invited. Freiburg, DE.
- 2018. Metabolic Vulnerabilities of Cancer. Invited. Salt Lake City, US.
- 2018. Metabolic Vulnerabilities of Cancer. Conference. Keystone Symposium on Tumor Metabolism. Snowbird, US.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. Milan, IT.
- 2017. Metabolic Vulnerabilities of Cancer. Conference. Metabolomics China. Shanghai, CN.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. Beijing, CN.
- 2017. Metabolic Vulnerabilities of Cancer. Conference. MD Anderson Cancer Center Symposium. Houston, US.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. Dallas, US.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. Frankfurt, DE.
- 2017. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Conference. 42nd Congress of The Federation of the European Biochemical Societies (FEBS). Jerusalem, IL.
- 2017. Emerging topics in developmental therapeutics: Targeting Metabolism. Conference. ESMO 2017 Congress. Madrid, ES.
- 2017. Metabolic Vulnerabilities of Cancer. Conference. Markey Cancer Center Conference on Cancer and Metabolism. Lexington, US.
- 2017. Targeting Metabolic Vulnerabilities of Cancer. Conference. Beatson International Cancer Conference. Glasgow, GB.
- 2017. Tageting oxidative phosphorylation to eradicate leukemic stem cells. Conference. EHA Annual Conference. Madrid, ES.
- 2017. Metabolic Vulnerabilities of Cancer. Invited. South California Metabolic Consortium. Los Angeles, US.
- 2017. Metabolic Adaptations to Redox Stress. Conference. Hinterzartener Kreis Symposium. Cadenabbia, IT.
- 2017. The onco-metabolic role and liabilities of the TCA cycle in cancer. Conference. EACR-OECI Conference, Cancer Precision Medicine. Amsterdam, NL.
- 2017. Targeting Oxidative Phosphorylation to Eradicate Leukemic Stem Cells. Conference. Keystone Symposia on Adaptations to Hypoxia in Physiology and Disease. Whistler, CA.
- 2017. Tumorigenic Mechanisms of TCA-Cycle Deficient Tumors. Conference. Keystone Symposia on Mitochondria Communication. Taos, US.
- 2016. Educational session: Metabolism and cancer. Conference. ESMO Asia Congress, SG.
- 2016. Targeting Oxidative Phosphorylation to Eradicate Leukemic Stem Cells. Conference. 3rd International Society of Cancer Metabolism Meeting. Brussels, BE.
- 2016. Tumorigenic Mechanisms of TCA Cycle Deficient Cancers. Conference. EMBO Workshop on Cancer Metabolism. Bilbao, ES.
- 2016. Tumorigenic Mechanisms of TCA Cycle Deficient Cancers. Conference. 24th Biennial Congress of the European Association for Cancer Research. Manchester, GB.
- 2016. Exposing and exploiting cancer’s metabolic vulnerabilities. Conference. Company of Biologists Workshop on Metabolism. Wilton Park, GB.
- 2016. Workshop: Metabolic Rewiring of Cancer. Conference. AACR Annual Meeting. New Orleans, US.
- 2016. Glutamine Metabolism in Glioblastoma. Conference. AACR Annual Meeting. New Orleans, US.
- 2016. Metabolic Vulnerabilities of Cancer. Invited. Cincinnati, US.
- 2015. Tumorigenic mechanisms and druggable vulnerabilities of TCA cycle deficient cancers. Invited. Tubingen, DE.
- 2015. Metabolic adaptations and liabilities of TCA cycle truncated tumors. Conference. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. Boston, US.
- 2015. Metabolic adaptations and essentialities of TCA cycle deficient tumors. Invited. Epigen-Chromatin Seminar. Rome, IT.
- 2015. Metabolic control of cell's fate. Conference. ECDO Annual Meeting. Geneva, CH.
- 2015. Symbiotic glutamine metabolism between astrocytes and glioblastoma cells. Conference. Abcam Conference: Cancer and Metabolism. Cambridge, GB.
- 2015. Targeting fatty acid synthesis under metabolic stress. Conference. Cell Death Symposium. Cold Spring Harbor, US.
- 2015. Symbiotic glutamine metabolism between astrocytes and glioblastoma cells. Conference. Banbury Meeting on Cancer and Metabolism. Cold Spring Harbor, US.
- 2015. De-novo purine biosynthesis dictates glutamine dependency of glioblastoma cells. Conference. AACR Special Conference: Metabolism and Cancer. Bellevue, US.
- 2015. Metabolic adaptations and vulnerabilities of SDH-deficient tumors. Conference. International Titisee Conferences on Cancer and Metabolism. Titisee, DE.
- 2015. Identifying and targeting metabolic vulnerabilities of cancer. Invited. Houston, US.
- 2015. Adaptable nutritional utilization in cancer cells under environmental stress. Conference. EACR Precision Medicine for Cancer Meeting, LU.
- 2015. Metabolic vulnerabilities of SDH-deficient tumors. Conference. Keystone Symposium on Tumor Metabolism. Vancouver, CA.
- 2014. The Hallmarks of Cancer: Metabolism. Conference. EANM Annual Meeting. Gothenburg, SE.
- 2014. Alternating nutritional sources of cancer. Conference. Cancer Metabolism: Mechanisms, Consequences and Therapeutic Opportunities. Smolenice Castle (Bratislava), SK.
- 2014. Metabolic Vulnerabilities of Cancer. Invited. Chicago, US.
- 2014. ACSS2 as a target in cancer metabolism. Conference. Systems Approach in Metabolic Diseases. Chicago, US.
- 2014. Metabolic Vulnerabilities of Melanoma. Conference. International Pigment Cell Conference, SG.
- 2014. Using metabolomics to reveal mechanism of transformation, biomarkers and vulnerabilities of FH-deficient tumors. Conference. Mechanisms and Models of Cancer. Cold Spring Harbor, US.
- 2014. Metabolic Vulnerabilities of SDH-deficient tumors. Conference. Euromit 2014 – International Meeting on Mitochondrial Pathology. Tampere, FI.
- 2014. Probing the metabolic plasticity of cancer. Panelist. Metabolomics: Following the Carbons that Fuel Cancer. Virtual.
- 2014. Metabolic Vulnerabilities of SDH-deficient tumors. Conference. Tumor Metabolism. Whistler, CA.
- 2013. Adaptable nutritional utilization in cancer cells under environmental stress. Invited. Barcelona, ES.
- 2013. Targeting Metabolism in Cancer. Invited. Boston, US.
- 2013. Metabolic networks in Cancer Discovery. Invited. Cambridge, US.
- 2013. The metabolic phase of the cell cycle. Conference. Molecular Cancer Therapeutics. Boston, US.
- 2013. Metabolic control of cell proliferation. Conference. Cancer & Metabolism. Athens, GR.
- 2013. Metabolic control of cell proliferation. Conference. Berlin, DE.
- 2013. Metabolic control of cell proliferation. Conference. AACR Annual Meeting. Washington, US.
- 2013. Metabolism and Cancer. Conference. AACR Annual Meeting. Washington, US.
- 2012. Metabolic control of the cell cycle. Conference. Banbury Meeting on Metabolism in Cancer. Cold Spring Harbor, US.
- 2012. Metabolism and Cancer. Invited. FEBS Congress. Seville, ES.
- 2012. Metabolic Transformation of Cancer. Conference. EACR Annual Meeting. Barcelona, ES.
- 2012. Anabolic processes in cancer. Conference. Growth Regulation by the TOR pathway. Les Treilles, Tourtour, FR.
- 2012. Utilizing metabolomics to identify novel therapeutic targets of cancer. Invited. Paris, FR.
- 2012. Metabolism, Metabolomics and Metabodynamics of Cancer. Invited. Rochester, US.
- 2012. Pyruvate Kinase M2 : linking glycolysis to amino acid biosynthesis. Conference. AACR Annual Meeting. Chicago, US.
- 2012. Cancer and Metabolism. Invited. Dublin, IE.
- 2012. Utilizing metabolomics to identify molecular targets for cancer therapeutic. Invited. La Jolla, US.
- 2012. Metabolism, Metabolomics and Metabodynamics of Cancer. Conference. Keystone Symposium on Cancer and Metabolism. Banff, CA.
- 2012. Metabolic control of cell’s fate. Conference. EACR Meeting on Apoptosis and Cell Death. Amsterdam, NL.
- 2011. On cancer, metabolism and apoptosis. Invited. Amsterdam, NL.
- 2011. Metabolic network approaches for cancer research. Conference. ECDO Annual Meeting. Stockholm, SE.
- 2011. Metabolic network approaches for cancer therapy. Conference. Gordon Conference: Metabolic Pathways. Waterville Valley, US.
- 2011. Metabolic Synthetic Lethality in TCA cycle deficient tumors. Invited. Sigma-Tau Fondazione Seminar. Rome, IT.
- 2011. Metabolomics approaches for cancer therapy. Invited. Zurich, CH.
- 2011. Metabolic network approaches for cancer therapy. Conference. CSHL Symposium on Metabolism and Disease. Cold Spring Harbor, US.
- 2011. Metabolomics approaches for cancer therapy. Invited. Bergen, NO.
- 2011. From metabolomics to system biology: identifying potential new targets for cancer therapy. Invited. Leuven, BE.
- 2011. From metabolomics to system biology: identifying potential new targets for cancer therapy. Conference. Nobel Forum: Frontiers in Cancer Research. Stockholm, SE.
- 2010. Metabolic transformation in cancer: novel pathways, new targets. Conference. Therapeutics Opportunities of Cancer Metabolism and Cell Death. Capri, IT.
- 2010. Metabolic transformation in cancer: novel pathways, new targets. Conference. ESMO Annual Meeting. Milan, IT.
- 2010. Targeting Metabolic Transformation for Cancer Therapy. Invited. Berlin, DE.
- 2010. Targeting Metabolic Transformation for Cancer Therapy. Conference. EACR Annual Meeting. Oslo, NO.
- 2010. Identifying new therapeutic targets in cancers with OXPHOS deficiencies. Conference. Keystone Symposium on Metabolism and Cancer. Vancouver, CA.
- 2009. Novel metabolic targets for cancer therapy. Conference. CNIO Cancer Conference: The Energy of Cancer. Madrid, ES.
- 2009. HIF prolyl hydroxylases: from functional tumor suppressors to metabolic sensors. Conference. AACR - Frontiers in Basic Cancer Research. Boston, US.
- 2009. HIF prolyl hydroxylases: from functional tumor suppressors to metabolic sensors. Conference. EMBO Workshop on Mitochondria and Cancer. Prague, CZ.
- 2009. On Metabolism and Cancer. Invited. Columbus, US.
- 2009. HIF prolyl hydroxylases: from functional tumor suppressors to metabolic sensors. Panelist. NCI Workshop on Cancer Metabolism. Bethesda, US.
- 2009. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. Conference. The Irish Association for Cancer Research Annual Meeting. Athlone, IE.
- 2009. International Seminar. None. Belfast, GB.
- 2009. International Seminar. None. Geneva, CH.
- 2009. International Seminar. None. Philadelphia, US.
- 2008. International Seminar. None. Biotech Research and Innovation Centre. Copenhagen, DK.
- 2008. N/A. Invited. Cell Growth and the TOR Pathway, FR.
- 2008. International Seminar. None. Cork, IE.
- 2008. International Seminar. None. Orlando, US.
- 2007. N/A. Invited. AACR Annual Meeting. Los Angeles, US.
- 2007. International Seminar. None. Philadelphia, US.
- 2007. International Seminar. None. Wuerzburg, DE.
- 2007. N/A. Invited. AACR/NCI/EORTC Cancer Therapeutics. San Francisco, US.
- 2006. N/A. Invited. The Steiner Foundation Meeting on Metabolism and Cancer. Brunnen, CH.
- 2006. International Seminar. None. Milan, IT.
- 2006. N/A. Invited. AACR Annual Meeting. Washington, US.
- 2006. N/A. Invited. European Bioenergetics Society Annual Meeting. Moscow, RU.
- 2005. International Seminar. None. Padova, IT.
Patient Reviews
CV information above last modified January 24, 2025